Title |
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
|
---|---|
Published in |
Blood, January 2015
|
DOI | 10.1182/blood-2014-09-598763 |
Pubmed ID | |
Authors |
Eric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, Ranjana H Advani, Jane N Winter, Celeste M Bello, Gary Spitzer, Maria Corinna Palanca-Wessels, Dana A Kennedy, Pamela Levine, Jing Yang, Nancy L Bartlett |
Abstract |
Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse large B-cell lymphoma (DLBCL), variably express CD30. This phase 2, open-label study evaluated efficacy of brentuximab vedotin, an anti-CD30 antibody-drug conjugate, in relapsed/refractory CD30-positive NHL. This planned subset analysis of B-cell NHLs includes 49 DLBCL patients and 19 with other B-cell NHLs. Objective response rate (ORR) was 44% for DLBCL, including 8 (17%) complete remissions (CR) with a median duration of 16.6 months thus far (range, 2.7 - 22.7+). There was no statistical correlation between response and level of CD30 expression; however, all responding patients had quantifiable CD30 by computer-assisted assessment of immunohistochemistry. DLBCL patients were generally refractory to frontline (76%) and most recent therapies (82%), and 44% of these refractory patients responded (15% CR). Patients with other B-cell lymphomas also responded: 1 CR, 2 PRs of 6 with gray zone, 1 CR of 6 with primary mediastinal B-cell, and 1 CR of 3 with post-transplant lymphoproliferative disorder. Adverse events were consistent with known toxicities. Combining brentuximab vedotin with rituximab was generally well tolerated with similar activity. Overall, significant activity with brentuximab vedotin was observed in refractory DLBCL and responses occurred across a range of CD30 expression. This study was registered at www.clinicaltrials.gov, NCT01421667. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 4 | 44% |
Germany | 1 | 11% |
Belgium | 1 | 11% |
Unknown | 3 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 67% |
Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Scientists | 1 | 11% |
Science communicators (journalists, bloggers, editors) | 1 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Hungary | 1 | <1% |
Germany | 1 | <1% |
Netherlands | 1 | <1% |
United Kingdom | 1 | <1% |
Peru | 1 | <1% |
United States | 1 | <1% |
Unknown | 203 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 41 | 20% |
Other | 32 | 15% |
Student > Ph. D. Student | 18 | 9% |
Student > Doctoral Student | 18 | 9% |
Student > Bachelor | 14 | 7% |
Other | 38 | 18% |
Unknown | 48 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 108 | 52% |
Biochemistry, Genetics and Molecular Biology | 8 | 4% |
Chemistry | 7 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 3% |
Agricultural and Biological Sciences | 5 | 2% |
Other | 19 | 9% |
Unknown | 56 | 27% |